Zentalis Pharmaceuticals Appoints Dr. Jan Skvarka to its Board of Directors
Retrieved on:
Monday, September 12, 2022
CD47, Therapy, Novosibirsk State University of Economics and Management, COVID-19, Partner, U.S. Securities and Exchange Commission, Company, Acquisition, Form 10-K, Economics, Harvard Business School, Industry, Bain & Company, MBA, BS, Board of directors, Private Securities Litigation Reform Act, Doctor of Philosophy, Failure, Board, SAN, GLOBE, SEC, DEM, University, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Cancer, Executive, Pfizer, Management, Pharmaceutical industry, Trillium
Dr. Skvarka is an accomplished biopharmaceutical executive bringing over three decades of extensive operational, strategic and financial expertise to Zentalis.
Key Points:
- Dr. Skvarka is an accomplished biopharmaceutical executive bringing over three decades of extensive operational, strategic and financial expertise to Zentalis.
- We are excited to welcome Jan, an experienced life sciences leader, to our Board of Directors, said Dr. Kimberly Blackwell, Chief Executive Officer of Zentalis.
- I am thrilled to be joining Zentalis passionate team at this pivotal time in the Companys trajectory, said Dr. Skvarka.
- Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers.